Big pharma’s biggest spenders revealed: 2022 edition
Pfizer’s buying spree propels it up the rankings, while Lilly continues to turn (relatively) small spend into big value.
A lean first quarter for venture-backed developers
While venture investors keep the purse strings tight, they themselves continue to enjoy fundraising success.
Novartis trims its pipeline
Discontinuations for branaplam, iptacopan and Piqray could increase pipeline scepticism, but more pruning is coming.
When is big pharma no longer big pharma?
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.